tetano
Editor, Senior Moderator
J Mov Disord. 2020 Apr 30. doi: 10.14802/jmd.20042. [Epub ahead of print]
COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson's Disease Patient Care.
Bhidayasiri R[SUP]1[/SUP], Virameteekul S[SUP]1[/SUP], Kim JM[SUP]2[/SUP], Pal PK[SUP]3[/SUP], Chung SJ[SUP]4[/SUP].
Author information
Abstract
While many infectious disorders are unknown to most neurologists, COVID-19 is very different. It has impacted neurologists and other health care workers, not only in our professional lives but also through the fear and panic within our own families, colleagues, patients and their families, and even in the wider public. COVID-19 affects all sorts of individuals, but the elderly with underlying chronic conditions are particularly at risk of severe disease, or even death. Parkinson's disease (PD) shares a common profile as an age-dependent degenerative disorder, frequently associated with comorbidities, particularly cardiovascular diseases, so PD patients will almost certainly fall into the high-risk group. Therefore, the aim of this review is to explore the risk of COVID-19 in PD based on the susceptibility to severe disease, its impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak, where neurologists face various challenges on how we can maintain effective care for PD patients without exposing them, or ourselves, to the risk of infection. It is less than six months since the identification of the original COVID-19 case on New Year's Eve 2019, so it is still too early to fully understand the natural history of COVID-19 and the evidence on COVID-19-related PD is scant. Though the possibilities presented are speculative, they are theory-based, and supported by prior evidence from other neurotrophic viruses closely related to SARS-CoV-2. Neurologists should be on high alert and vigilant for potential acute and chronic complications when encountering PD patients who are suspected of having COVID-19.
KEYWORDS:
COVID-19; Coronavirus; Pandemic; Parkinson’s disease; SARS-CoV-19
PMID:32344993DOI:10.14802/jmd.20042
Free full text
COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson's Disease Patient Care.
Bhidayasiri R[SUP]1[/SUP], Virameteekul S[SUP]1[/SUP], Kim JM[SUP]2[/SUP], Pal PK[SUP]3[/SUP], Chung SJ[SUP]4[/SUP].
Author information
Abstract
While many infectious disorders are unknown to most neurologists, COVID-19 is very different. It has impacted neurologists and other health care workers, not only in our professional lives but also through the fear and panic within our own families, colleagues, patients and their families, and even in the wider public. COVID-19 affects all sorts of individuals, but the elderly with underlying chronic conditions are particularly at risk of severe disease, or even death. Parkinson's disease (PD) shares a common profile as an age-dependent degenerative disorder, frequently associated with comorbidities, particularly cardiovascular diseases, so PD patients will almost certainly fall into the high-risk group. Therefore, the aim of this review is to explore the risk of COVID-19 in PD based on the susceptibility to severe disease, its impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak, where neurologists face various challenges on how we can maintain effective care for PD patients without exposing them, or ourselves, to the risk of infection. It is less than six months since the identification of the original COVID-19 case on New Year's Eve 2019, so it is still too early to fully understand the natural history of COVID-19 and the evidence on COVID-19-related PD is scant. Though the possibilities presented are speculative, they are theory-based, and supported by prior evidence from other neurotrophic viruses closely related to SARS-CoV-2. Neurologists should be on high alert and vigilant for potential acute and chronic complications when encountering PD patients who are suspected of having COVID-19.
KEYWORDS:
COVID-19; Coronavirus; Pandemic; Parkinson’s disease; SARS-CoV-19
PMID:32344993DOI:10.14802/jmd.20042
Free full text